Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase
Renibus Therapeutics Announces Participation at the Oppenheimer Private Life [...]
Renibus Therapeutics Announces Oral Presentation on Phase 3 PROTECT Trial Data for RBT-1 at the American Association for Thoracic Surgery (AATS) Annual Meeting
Renibus Therapeutics Announces Oral Presentation on Phase 3 PROTECT [...]
Renibus Therapeutics Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
Renibus Therapeutics Announces Participation at the 25th Annual Needham [...]
Renibus Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference
Renibus Therapeutics Announces Participation at the 36th Annual Oppenheimer [...]
Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)
Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for [...]
Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)
Renibus Therapeutics Announces Poster Presentation on RBT-1 at the [...]
Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac Surgery
Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal [...]
Renibus to Participate in the 24th Annual Needham Healthcare Virtual Healthcare Conference
Renibus to Participate in the 24th Annual Needham Healthcare Virtual [...]
Renibus to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Renibus to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences [...]
Renibus Therapeutics Announces Oral Presentation on RBT-1 at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
Renibus Therapeutics Announces Oral Presentation on RBT-1 at the 38th [...]